The Effect of SGLT2 Inhibitor Therapy on Endothelial Progenitor Cell Function in Patients With Heart Failure

Area of Science:

• Cardiology
• Pharmacology
• Cell Biology

Background:

• Sodium-glucose cotransporter-2 (SGLT-2) inhibitors demonstrate cardiovascular benefits in heart failure (HF) patients.
• The precise mechanisms underlying these benefits remain unclear.
• Endothelial progenitor cells (EPCs) play a crucial role in vascular repair and endothelial function.

Purpose of the Study:

• To investigate the impact of SGLT-2 inhibitors on the levels and function of circulating EPCs in patients with symptomatic HF.
• To explore whether changes in EPCs contribute to the therapeutic effects of SGLT-2 inhibitors in HF.

Main Methods:

• A cohort of 20 patients with symptomatic HF (both HFpEF and HFrEF) was studied.
• Blood samples were collected at baseline and after at least 3 months of SGLT-2 inhibitor treatment.
• EPC levels were assessed using flow cytometry (VEGFR-2, CD34, CD133 expression), and EPC function was evaluated by colony-forming unit (CFU) assays.

Main Results:

• SGLT-2 inhibitor therapy significantly increased the proportion of circulating EPCs expressing VEGFR-2/CD34 and VEGFR-2/CD133.
• A significant increase in EPC colony-forming units (CFUs) was observed after SGLT-2 inhibitor treatment.
• These findings indicate enhanced EPC levels and function post-treatment.

Conclusions:

• Treatment with SGLT-2 inhibitors is associated with an augmentation of circulating EPCs in patients with HF (both HFpEF and HFrEF).
• The observed increase in EPC levels and function may represent a key mechanism contributing to the cardiovascular protective effects of SGLT-2 inhibitors in HF.
• Further research is warranted to fully elucidate the role of EPCs in SGLT-2 inhibitor-mediated cardiovascular benefits.